Transcatheter left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: results from the Belgian registry

被引：13

作者：

Kefer, Joelle ^{[1
]}

Aminian, Adel ^{[2
]}

Vermeersch, Paul ^{[3
]}

de Potter, Tom ^{[4
]}

Stammen, Francis ^{[5
]}

Benit, Edouard ^{[6
]}

Budts, Werner ^{[7
]}

Missault, Luc ^{[8
]}

Drieghe, Benny ^{[9
]}

Buysschaert, Ian ^{[10
]}

Cornelis, Kristoff ^{[11
]}

Herzet, Jean-Manuel ^{[12
]}

Guedes, Antoine ^{[13
]}

Debbas, Nadia ^{[14
]}

Rivero, Maximo ^{[15
]}

Lempereur, Mathieu ^{[16
]}

Lochy, Stijn ^{[17
]}

Casado-Arroyo, Ruben ^{[18
]}

Laruelle, Christophe ^{[19
]}

Debruyne, Philippe ^{[20
]}

Ledent, Thierry ^{[21
]}

机构：

[1] Clin Univ St Luc, Brussels, Belgium

[2] CHU Charleroi, Charleroi, Belgium

[3] Middelheim ZNA, Antwerp, Belgium

[4] Onze Lieve Vrouw Hosp, Aalst, Belgium

[5] AZ Delta Roeselare, Roeselare, Belgium

[6] Jessaziekenhuis, Hasselt, Belgium

[7] Gasthuisberg UZ Leuven, Leuven, Belgium

[8] Acad Hosp St Jan, Brugge, Belgium

[9] UZ Gent, Ghent, Belgium

[10] ASZ Aalst, Aalst, Belgium

[11] Marie Middelares, Ghent, Belgium

[12] CHR Citadelle, Liege, Belgium

[13] CHU UcL Namur, Yvoir, Belgium

[14] CHU St Pierre, Brussels, Belgium

[15] Ziekenhuis Oost Limburg, Genk, Belgium

[16] CHU Liege, Liege, Belgium

[17] UZBrussel, Brussels, Belgium

[18] Erasme ULB, Brussels, Belgium

[19] St Luc Bouge, Bouge, Belgium

[20] Imelda Ziekenhuis, Bonheiden, Belgium

[21] CHU Tivoli, La Louviere, Belgium

来源：

EUROINTERVENTION | 2018年 / 13卷 / 13期

关键词：

atrial fibrillation; bleeding; specific device closure/technique; stroke; ORAL ANTICOAGULATION; WARFARIN THERAPY; CONSENSUS REPORT; WATCHMAN DEVICE; CLINICAL-TRIALS; CLOSURE; DEFINITIONS; MULTICENTER; SAFETY; RISK;

D O I：

10.4244/EIJ-D-17-00076

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims: This study aimed to assess the safety and efficacy at midterm follow-up of left atrial appendage occlusion (LAAO) using different devices, in real life in Belgium. Methods and results: Between June 2009 and November 2016, 457 consecutive patients (63% male, 75 +/- 12 yrs, CHA(2)DS(2)-VASc 4 +/- 0.6, HAS-BLED 3.5 +/- 0.7) undergoing LAAO were included. Technical success was 97.1%. There were 19 periprocedural major adverse events (4.1%) including three deaths (0.6%), nine tamponades (1.9%), four major bleedings (0.8%) and two device embolisations (0.4%). Among patients successfully implanted having a complete follow-up (672 patient-years, median follow-up 370 days), the actual annual stroke rate was 1.2%, lower than the expected stroke risk of 4% (70% reduction). The observed bleeding rate was 2%, while the calculated risk was 3.7% (46% reduction). Kaplan-Meier analysis showed a similar overall survival (93 +/- 2% and 87 +/- 3% versus 91 +/- 3% and 87 +/- 4%; p=0.35) and event-free survival (92 +/- 2% and 84 +/- 3% versus 88 +/- 3% and 80 +/- 5%; p=0.17) at one and two years, for the ACP/Amulet versus the WATCHMAN groups of patients, respectively. Conclusions: The data from the Belgian left atrial appendage occlusion registry suggest that the procedure is effective and relatively safe in a real-world setting, using either the WATCHMAN or the ACP/Amulet device.

引用

页码：1603 / 1611

页数：9